No Data
No Data
Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium
Cyclacel Pharmaceuticals Files for Offering of Shares, Warrants
Cyclacel Pharmaceuticals Files to Sell Common Stock, Warrants, No Amount Given
Cyclacel Completes Enrollment of Biomarker-Based Patients in Phase 2 Fadraciclib Study
Express News | Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Express News | Cyclacel Pharmaceuticals: Passed Resolution to Suspend Qtrly Cash Dividend Payment on 6% Convertible Exchangeable Preferred Stock Scheduled Nov 1
No Data
No Data